# US 2022/0031503 A1 · Laser therapy for treatment and prevention of eye diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031503 A1
- Document ID: US20220031503A1
- Status: Published application
- Kind: A1
- Application number: 17/290,969
- Filed: 2019-11-04
- Published: 2022-02-03
- Earliest claimed: 2018-11-02
- Assignees: ALeyeGN Technologies LLC
- Applicants: Aleyegn Technologies LLC
- Inventors: Giorgio Dorin; John Randall Samples; Michael K. Ballard; Satish Herekar; William Eddington; Perry Binder
- Web page: https://patentgrep.com/patent/US20220031503A1

## CPC

- A61F 9/008: using laser
- A61F 9/00821: {for coagulation}
- A61F 2009/00865: {Sclera}
- A61F 2009/00868: {Ciliary muscles or trabecular meshwork}
- A61F 2009/00891: {Glaucoma}
- A61F 2009/00897: {Scanning mechanisms or algorithms}
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)

## Abstract

An ab externo automated laser treatment system for treating an eye in a subject, includes a non-contact laser source configured to generate a laser beam having at least one wavelength to treat the eye by directing the laser beam from a location spaced from the eye, wherein the at least one wavelength is a near-infrared wavelength in the range of about 0.5-2.2 μm, a laser scanner optically coupled to the non-contact laser source to receive the laser beam from the non-contact laser source and to scan the laser beam relative to the eye, and a processor, and memory including stored computer-readable instructions that, responsive to execution by the processor, cause the laser treatment system to direct the laser beam to a plurality of trans-scleral treatment locations to be irradiated in a predetermined treatment pattern on an external surface of the eye, wherein the trans-scleral treatment locations are 0-4 mm posterior to the corneolimbal junction, and wherein the laser beam is repetitively directed to the same irradiated trans-scleral treatment locations on the surface of the eye, and the trans-scleral treatment locations are irradiated at intervals sufficient to induce protective thermal preconditioning and therapeutic bio-stimulation of one or more of the trabecular meshwork and/or ciliary body without photocoagulation of the tissue of the eye. Trans-pupillary systems, patient interfaces, and methods are also disclosed.

## Claims

### Claim 1

An ab externo automated laser treatment system for treating an eye in a subject, comprising:
a non-contact laser source configured to generate a laser beam having at least one wavelength to treat the eye by directing the laser beam from a location spaced from the eye, wherein the at least one wavelength is a near-infrared wavelength in the range of about 0.5-2.2 μm;
a laser scanner optically coupled to the non-contact laser source to receive the laser beam from the non-contact laser source and to scan the laser beam relative to the eye; and
a processor, and memory including stored computer-readable instructions that, responsive to execution by the processor, cause the laser treatment system to direct the laser beam to a plurality of trans-scleral treatment locations to be irradiated in a predetermined treatment pattern on an external surface of the eye, wherein the trans-scleral treatment locations are 0-4 mm posterior to the corneolimbal junction, and wherein the laser beam is repetitively directed to the same irradiated trans-scleral treatment locations on the surface of the eye, and the trans-scleral treatment locations are irradiated at intervals sufficient to induce protective thermal preconditioning and therapeutic bio-stimulation of one or more of the trabecular meshwork and/or ciliary body without photocoagulation of the tissue of the eye.

### Claim 2 (depends on 1)

The system of claim 1, wherein the memory includes stored computer-readable instructions that cause the laser treatment system to direct the laser beam to a plurality of trans-pupillary treatment locations and to induce sublethal thermal elevations eliciting therapeutic biomodulation at the target eye tissue within a predetermined therapeutic temperature range, the plurality of trans-pupillary treatment locations including a predetermined curvilinear treatment pattern on target eye tissue of the eye comprising multiple concentric annuli on the macula around but not on the foveal avascular zone.

### Claim 3 (depends on 1)

The system of claim 1, wherein the memory includes stored computer-readable instructions that cause the laser treatment system to direct the laser beam to a plurality of trans-pupillary treatment locations and to induce sublethal thermal elevations eliciting therapeutic biomodulation at the target eye tissue within a predetermined therapeutic temperature range, the plurality of trans-pupillary treatment locations including an area (i) surrounding the macula, but not on the foveal avascular zone, and (ii) surrounding the optic disk, but not on the optic disk or adjacent peripapillary crescent.

### Claim 4 (depends on 1)

The system of claim 1, wherein the memory includes stored computer-readable instructions that cause the laser treatment system to direct the laser beam to a plurality of trans-pupillary treatment locations and to induce sublethal thermal elevations eliciting therapeutic biomodulation at the target eye tissue within a predetermined therapeutic temperature range, the plurality of trans-pupillary treatment locations including an area surrounding the optic disk, but not on the optic disk or adjacent peripapillary crescent.

### Claim 5 (depends on 1)

The system of claim 1, wherein the memory includes stored computer-readable instructions that cause the laser treatment system to direct the laser beam to a plurality of trans-pupillary treatment locations and to induce sublethal thermal elevations eliciting therapeutic biomodulation at the target eye tissue within a predetermined therapeutic temperature range, the plurality of trans-pupillary treatment locations including an area adjacent to the foveal avascular zone, but not on the area of the papillomacular bundle.

### Claim 6 (depends on 1)

The system of claim 1, wherein the stored computer-readable instructions cause the laser treatment system to direct the laser beam to the plurality of trans-scleral and/or trans-pupillary treatment locations with the subject having clinically normal intraocular pressure and/or having an absence of glaucoma symptoms or diagnosis.

### Claim 7 (depends on 1)

The system of claim 1, wherein the stored computer-readable instructions cause the laser treatment system to direct the laser beam to the plurality of trans-scleral treatment locations at the intervals sufficient to induce the protective thermal preconditioning and bio-stimulation of targeted structures eliciting biomechanical and biochemical responses to lower intraocular pressure.

### Claim 8 (depends on 1)

The system of claim 1, wherein the processor is configured with instructions to repetitively deliver the laser beam to the plurality of irradiated trans-scleral treatment locations at intervals that target an increase in the temperature of the outer 200-500 μm scleral layers to a temperature of about 45-57° C.

### Claim 9 (depends on 1)

The system of claim 1, wherein the laser parameters are configured to provide irradiance of the laser beam and a scanning speed with which the laser beam moves around the predetermined treatment pattern increases the temperature of the outer 200 μm scleral layers to the temperature of about 43-57° C., optionally about 43-45° C.

### Claim 10 (depends on 1)

The system of claim 1, wherein the processor is configured with instructions to receive an input corresponding to a location of the corneolimbal junction or limbus of the subject and wherein the processor is configured to determine the plurality of trans-scleral treatment locations in response to the input and wherein the plurality of trans-scleral treatment locations is offset radially outward from the input location corresponding to corneolimbal junction or limbus to contour the treatment pattern to the anatomy of the eye of the subject.

### Claim 11 (depends on 1)

The system of claim 1, wherein the trans-scleral treatment locations are in a 360° annular pattern posterior to the corneolimbal junction, and the processor is configured to direct the laser beam to a set of pre-identified trans-scleral treatment locations on the surface of the eye during a first treatment cycle, and during a subsequent treatment cycle direct the laser beam to the same pre-identified trans-scleral treatment locations, to achieve precise cyclic thermal elevation of scleral tissue underlying the pre-identified trans-scleral treatment locations at intervals of time with thermal relaxation of the irradiated tissue between treatment cycles.

### Claim 12 (depends on 11)

The system of claim 11, wherein the processor is configured to set the speed of each treatment cycle to achieve the thermal relaxation by spacing irradiation of the trans-scleral treatment locations at sufficient intervals that an exposure time and relaxation time produce a targeted time-temperature history.

### Claim 13 (depends on 1)

The system of claim 1, wherein the interval between irradiation of the same trans-scleral treatment location produces a duty factor, corresponding to the ratio between the active exposure ON time/(active exposure+relaxation OFF time), in the 2-50% range.

### Claim 14 (depends on 13)

The system of claim 13, wherein the interval between irradiation of the same trans-scleral treatment location is about 10-300 ms, optionally about 100-200 ms.

### Claim 15 (depends on 1)

The system of claim 1, wherein the predetermined treatment pattern is located about 1.5 mm posterior to the corneolimbal junction.

### Claim 16 (depends on 1)

The system of claim 1, wherein the predetermined treatment pattern comprises multiple annular treatment patterns, and wherein the multiple annular treatment patterns are spaced about 1.5 mm, 2.5 mm and 3.5 mm posterior to the corneolimbal junction, wherein the annular treatment patterns comprise one or more of circular, oval, elliptical, egg-like, non-circular, non-elliptical, or asymmetrical patterns, or patterns that correspond to the shape of Schlemm's canal or the limbus.

### Claim 17 (depends on 11)

The system of claim 11, wherein the 360° pattern is interrupted nasally by 10-30° and temporally by 10-30°.

### Claim 18 (depends on 16)

The system of claim 16, wherein the multiple annular treatment patterns target the
(a) perilimbal outflow structure;
(b) pars plicata; and
(c) pars plana.

### Claim at position 19

19-23. (canceled)

### Claim 24 (depends on 1)

The system of claim 1, wherein the protective thermal preconditioning and therapeutic bio-stimulation are controlled by one or more of the laser's power, irradiance, scanning speed, cycle repetition rate, number of cycle repetitions, spot size and duty cycle.

### Claim 25 (depends on 1)

The system of claim 1, wherein the processor is configured to direct the laser beam to the trans-scleral treatment location in a spot having a diameter of 500-1000 μm, optionally about 600 μm.

### Claim at position 22

26-34. (canceled)

### Claim 35 (depends on 2)

The system of claim 2, wherein each annulus on the macula of the curvilinear treatment pattern comprises a plurality of evenly-spaced and overlapping laser pulse spots sequentially delivered along a complete circle to produce an irradiated annular treatment zone within each annulus, wherein the laser pulse spots are delivered at a common scan speed for all macular annuli.

### Claim at position 24

36-37. (canceled)

### Claim 38 (depends on 1)

The system of claim 1, wherein the laser source is configured to produce the laser beam with pulses at a pulse repetition period in the range of 1-3 ms, pulse repetition rate of 1000 to 333 pulses per second and a pulse duration in the range of 20-500 μs.

### Claim at position 26

39-40. (canceled)

### Claim 41 (depends on 2)

The system of claim 2, wherein the annuli comprise three to five contiguous concentric annuli on the macula, each annulus having a substantially equal width, and wherein the plurality of trans-scleral treatment locations comprises three concentric annuli on the sclera around the limbus at radii R1, R2 and R3 that correspond respectively to locations overlying the primary aqueous outflow pathway, the pars plicata ciliary body, and the pars plana.

### Claim 42 (depends on 2)

The system of claim 2, wherein the annuli comprise five contiguous annuli on the macula, each annulus having a width of approximately 500 microns, and wherein the plurality of trans-scleral treatment locations comprises three concentric annuli on the sclera at distances of approximately 1.5, 2.5 and 3.5 mm from the corneoscleral junction.

### Claim 43 (depends on 2)

The system of claim 2, wherein the sublethal thermal elevations correspond to a raise in the temperature of the target tissue in the annuli on the macula to a temperature of no more than 47° C., and the laser beam raises the temperature of the target tissue in the trans-scleral treatment locations to no more than 57° C.

### Claim 44 (depends on 2)

The system of claim 2, wherein the laser source comprises a first diode laser source operable to produce a pulsed laser beam at 810 nm for directing to the trans-pupillary treatment locations, a second diode laser source operable to produce a continuous-wave laser beam at 1475 nm for directing to the trans-scleral treatment locations, and at least one beam splitter situated to receive and direct the beam at 810 nm and the beam at 1475 nm along a common optical path for receiving by the laser scanner.

### Claim 45

(canceled)

### Claim 46

An ab externo automated method for treating an eye in a subject, the method comprising:
directing laser energy having a near-infrared wavelength of about 0.5-2.2 μm from a location spaced from the eye to a plurality of trans-scleral treatment locations to be irradiated in a predetermined treatment pattern on an external surface of the eye, wherein the trans-scleral treatment locations are 0-4 mm posterior to the corneolimbal junction, and wherein the laser energy is repetitively directed to the same irradiated trans-scleral treatment locations on the surface of the eye, and the trans-scleral treatment locations are irradiated at intervals sufficient to induce protective thermal preconditioning and therapeutic bio-stimulation of one or more of the trabecular meshwork and/or ciliary body without photocoagulation of the tissue of the eye.

### Claim at position 33

47-103. (canceled)
